RxDoctor Payments Data

Jill McEachern, APRN

Women's Health · Guilford, CTNPI 1053392837

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 38.8% of the total. Reporting peaked in 2021 at $204 and has fallen 75.6% since, to $50 in 2023.

$371in general payments, 2019–2025

Across 21 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$144
  • AstraZeneca$73
  • Pfizer$46
  • Paratek Pharmaceuticals, Inc.$36
  • Amarin Pharma, Inc.$33
  • Lilly USA, LLC$28
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 70th percentile of 53 women's health providers in Connecticut.

See all women's health providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,752
Medicare patients
60
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$27,949
OzempicSemaglutide27$27,386
EliquisApixaban18$16,269
JanuviaSitagliptin Phosphate13$16,183
MounjaroTirzepatide15$16,042
Wixela InhubFluticasone Propion/Salmeterol40$3,355
Levothyroxine Sodium81$1,117
Atorvastatin Calcium161$1,099
Rosuvastatin Calcium60$721
Amlodipine Besylate89$601
Albuterol Sulfate HfaAlbuterol Sulfate45$572
Losartan Potassium57$546
Venlafaxine Hcl ErVenlafaxine Hcl20$457
Lisinopril80$375
Bupropion XlBupropion Hcl12$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$73$27,94919 claims
PfizerEliquis$46$16,26918 claims
Lilly USA, LLCMounjaro$28$16,04215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 53 women's health providers in Connecticut.

Other women's health in Guilford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →